Erol Erduran

Erol Erduran

Auto-generated profile, based on publicly available information

Erol Erduran

Department of Pediatric Hematology and Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
EEErol Erduran
Erol Erduran
ABAysenur Bahadir
Aysenur Bahadir
NPNil Palanci
Nil Palanci
YGYusuf Gedik
Yusuf Gedik
Crimean-Congo hemorrhagic fever (CCHF) is an acute tick-borne disease caused by Nairovirus, and it is sometimes characterized by reactive hemophagocytic histiocytosis (HLH). The reasons for reactive HLH are macrophage-activating syndrome and disseminated intravascular coagulation due to cytokine storm, liver dysfunction, and endothelial damage by the virus. In this study, the effectiveness of high-dose methylprednisolone (HDMP) (5 to 30 mg/kg/d), fresh frozen plasma (FFP), and intravenous immunoglobulin (IVIG) was investigated in patients with CCHF associated with reactive HLH. Twelve patients with CCHF in association with reactive HLH were included in the study. The patients were successfully treated with HDMP to suppress the macrophage activation, FFP to treat disseminated intravascular coagulation, and IVIG to treat severe thrombocytopenia. No patients received ribavirin. Fever reduced in 1.6 ± 0.8 days, WBC count increased above 4.500/µL in 4.0 ± 2.4 days, platelet count increased above 150.000/µL in 8.5 ± 2.5 days, and D-dimer level decreased under 1 mcg/dL in 5.8 ± 3.6 days. Consequently, HDMP, FFP, and IVIG may be effective in patients with CCHF associated with reactive HLH during hemorrhagic period of the disease.

1 April 2010 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
EEErol Erduran
Erol Erduran
MMMelike Makuloglu
Melike Makuloglu
MMMehmet Mutlu
Mehmet Mutlu

1 April 2009 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
EEErol Erduran
Erol Erduran
AAAyşe Aksoy
Ayşe Aksoy
DZDilek Zaman
Dilek Zaman
Glanzmann's thrombasthenia is an inherited platelet function disorder caused by quantitative or qualitative defects of the platelet membrane glycoprotein IIb/IIIa complex. Activated recombinant factor VII (rFVIIa) has recently been used in the treatment of patients with Glanzmann's thrombasthenia. We report herein a 16-year-old boy with Glanzmann's thrombasthenia who did not respond to conservative treatment for excessive bleeding and hyperfibrinolysis after tonsillectomy and who was successfully treated with rFVIIa. We suggest that rFVIIa at repeated doses of 80-100 microg/kg may be used effectively in patients with Glanzmann's thrombasthenia having excessive bleeding associated with hyperfibrinolysis after tonsillectomy in addition to tranexamic acid treatment.

17 March 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
AYAyça Koca Yozgat
Ayça Koca Yozgat
GLGöksel Leblebisatan
Göksel Leblebisatan
SASinan Akbayram
Sinan Akbayram
SÖSimge Çınar Özel
Simge Çınar Özel
ZKZeynep Karakaş
Zeynep Karakaş
NÖNamık Yaşar Özbek
Namık Yaşar Özbek
Objective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5 +/- 4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of >= 50x109/L was 11.6 +/- 8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8 +/- 9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.

1 June 2011 in Turkish Journal of Hematology
Verified
Journal Article
Open access
MMMehmet Mutlu
Mehmet Mutlu
EEErol Erduran
Erol Erduran
YAYakup Aslan
Yakup Aslan
This study aimed to determine the etiologic factors of acquired methemoglobinemia in infants younger than three months in our region. This study was carried out retrospectively in infants with methemoglobinemia admitted to Karadeniz Technical University, Pediatric Clinic, during the period 2000-2009. Infants with methemoglobinemia were identified according to the medical records or ICD-10 code. Nine infants with acquired methemoglobinemia (8 male, 1 female) were included in the study. Seven cases were associated with the use of prilocaine for circumcision, one case with the use of prilocaine-lidocaine for local pain therapy, and one case with neonatal sepsis caused by Staphylococcus aureus. Prilocaine should not be used in infants less than three months of age because of the risk of methemoglobinemia. Ascorbic acid is an effective therapy if methylene blue is not obtained. It should not be forgotten that sepsis caused by S. aureus may cause methemoglobinemia in infants.

29 January 1999 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
EEErol Erduran
Erol Erduran
YGYusuf Gedik
Yusuf Gedik
ARAbdulkadir Reis
Abdulkadir Reis
FOFazıl Orhan
Fazıl Orhan